DMIIU Files S-1 for SPAC IPO, Eyes 'Made In America' Drug Sector
Ticker: DMIIU · Form: S-1 · Filed: Jul 21, 2025 · CIK: 2040475
| Field | Detail |
|---|---|
| Company | Drugs Made In America Acquisition II Corp. (DMIIU) |
| Form Type | S-1 |
| Filed Date | Jul 21, 2025 |
| Risk Level | high |
| Sentiment | neutral |
Sentiment: neutral
Topics: SPAC, Blank Check Company, S-1 Filing, IPO, Acquisition, Pharmaceuticals, Biotech
Related Tickers: DMIIU
TL;DR
DMIIU is a new SPAC looking to buy a private drug company, so it's a pure bet on management's deal-making skills.
AI Summary
Drugs Made In America Acquisition II Corp. (DMIIU) filed an S-1 on July 21, 2025, as a blank check company, or SPAC, with the primary objective of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The filing indicates no current revenue or net income, as it is a newly formed entity specifically for an acquisition. Key business changes will occur upon the completion of a de-SPAC transaction, which is currently undefined. Risks include the inability to complete a suitable business combination within the specified timeframe, potential dilution for public shareholders, and the inherent uncertainties of identifying and acquiring a target company. The strategic outlook is entirely dependent on successfully identifying and merging with a private company, ideally within the 'Drugs Made In America' sector, to bring it public. The company's principal executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301, with a business phone of (954) 870-3104.
Why It Matters
This S-1 filing signals the intent of Drugs Made In America Acquisition II Corp. to raise capital through an IPO to acquire a private company, potentially bringing a new player to the public markets. For investors, it represents a speculative opportunity in a SPAC, with returns contingent on the management team's ability to identify and execute a value-accretive merger, particularly within the 'Made In America' drug manufacturing space. Employees of a future target company could see significant changes in compensation and corporate structure. The broader market gains another SPAC, intensifying competition among blank check companies to find attractive private targets, especially in the competitive pharmaceutical and biotech sectors.
Risk Assessment
Risk Level: high — The risk level is high because DMIIU is a blank check company with no operations, revenue, or identified target business. The S-1 filing explicitly states its purpose is to effect a business combination, meaning its success is entirely dependent on future events and the ability to find a suitable acquisition within a limited timeframe, as is typical for SPACs.
Analyst Insight
Investors should approach DMIIU with caution, recognizing it as a speculative investment in a SPAC. Monitor for news regarding a potential target acquisition and thoroughly evaluate the target company's financials and business model once announced, as the initial investment is purely a bet on the sponsor's ability to execute a successful de-SPAC transaction.
Financial Highlights
- debt To Equity
- 0.0
- revenue
- $0
- operating Margin
- N/A
- total Assets
- $0
- total Debt
- $0
- net Income
- $0
- eps
- $0
- gross Margin
- N/A
- cash Position
- $0
- revenue Growth
- N/A
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Lynn Stockwell | Chief Executive Officer and Executive Chair | $0 |
Key Numbers
- 333-288791 — SEC File Number (Unique identifier for this S-1 registration statement)
- 954-870-3099 — Business Phone Number (Contact number for the registrant's principal executive offices)
- 6770 — Primary Standard Industrial Classification Code (Indicates the company is a 'Blank Check' company)
- 2025-07-21 — Filing Date (Date the S-1 was officially filed with the SEC)
Key Players & Entities
- Drugs Made In America Acquisition II Corp. (company) — Registrant and blank check company
- Lynn Stockwell (person) — Chief Executive Officer and Executive Chair
- Mitchell S. Nussbaum, Esq. (person) — Counsel from Loeb & Loeb LLP
- G. Alex Weniger-Araujo, Esq. (person) — Counsel from Loeb & Loeb LLP
- Douglas S. Ellenoff, Esq. (person) — Counsel from Ellenoff Grossman & Schole LLP
- Stuart Neuhauser, Esq. (person) — Counsel from Ellenoff Grossman & Schole LLP
- Anthony Ain, Esq. (person) — Counsel from Ellenoff Grossman & Schole LLP
- U.S. Securities and Exchange Commission (regulator) — Filing recipient
- Loeb & Loeb LLP (company) — Legal counsel for the registrant
- Ellenoff Grossman & Schole LLP (company) — Legal counsel for the registrant
FAQ
What is Drugs Made In America Acquisition II Corp.'s primary business purpose?
Drugs Made In America Acquisition II Corp.'s primary business purpose, as stated in its S-1 filing on July 21, 2025, is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Who is the CEO of Drugs Made In America Acquisition II Corp.?
Lynn Stockwell is identified as the Chief Executive Officer and Executive Chair of Drugs Made In America Acquisition II Corp., according to the S-1 filing dated July 21, 2025.
What is the risk level associated with investing in Drugs Made In America Acquisition II Corp.?
Investing in Drugs Made In America Acquisition II Corp. carries a high risk level because it is a blank check company with no current operations or identified target, making its success entirely dependent on a future, uncertain business combination.
Where are Drugs Made In America Acquisition II Corp.'s principal executive offices located?
The principal executive offices for Drugs Made In America Acquisition II Corp. are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301, with a business phone number of (954) 870-3104.
When was the S-1 filing for Drugs Made In America Acquisition II Corp. submitted?
The S-1 registration statement for Drugs Made In America Acquisition II Corp. was filed with the U.S. Securities and Exchange Commission on July 21, 2025, with a filing date as of change on July 18, 2025.
What type of company is Drugs Made In America Acquisition II Corp. based on its SIC code?
Based on its Primary Standard Industrial Classification Code of 6770, Drugs Made In America Acquisition II Corp. is classified as a 'Blank Check' company, indicating it is a SPAC formed for the purpose of an acquisition.
What legal firms are advising Drugs Made In America Acquisition II Corp. on this S-1 filing?
Loeb & Loeb LLP, with Mitchell S. Nussbaum, Esq. and G. Alex Weniger-Araujo, Esq., and Ellenoff Grossman & Schole LLP, with Douglas S. Ellenoff, Esq., Stuart Neuhauser, Esq., and Anthony Ain, Esq., are advising Drugs Made In America Acquisition II Corp. on this S-1 filing.
Does Drugs Made In America Acquisition II Corp. have any current revenue or net income?
No, as a newly formed blank check company, Drugs Made In America Acquisition II Corp. has no current revenue or net income, as its operations are solely focused on identifying and completing a business combination.
What is the significance of the 'II' in Drugs Made In America Acquisition II Corp.'s name?
The 'II' in Drugs Made In America Acquisition II Corp.'s name suggests it is the second special purpose acquisition company (SPAC) launched by the same sponsor or management team, indicating prior experience in the SPAC market.
What is the proposed sale date for Drugs Made In America Acquisition II Corp.'s securities?
The proposed sale to the public for Drugs Made In America Acquisition II Corp.'s securities is stated as 'As soon as practicable after the effective date of this registration statement,' without a specific calendar date.
Risk Factors
- Inability to Complete a Business Combination [high — financial]: The company has no operations or revenue and is dependent on completing a business combination within 24 months of its IPO. Failure to do so will result in liquidation and a return of funds to public shareholders, potentially at a loss.
- Potential Dilution [medium — financial]: The issuance of shares in connection with a business combination, including to sponsors and potentially through warrants, could significantly dilute the ownership interests of public shareholders.
- Target Identification Uncertainty [high — operational]: The success of the company is contingent on identifying and acquiring a suitable target business. There is no assurance that a suitable target will be found or that the proposed transaction will be consummated.
- SPAC Regulatory Scrutiny [medium — regulatory]: SPACs are subject to evolving regulatory scrutiny. Changes in regulations or interpretations could impact the company's ability to complete a transaction or the terms thereof.
- Market Volatility [medium — market]: The market for SPACs and de-SPAC transactions can be volatile. Adverse market conditions could impact the company's ability to raise capital or the valuation of a target business.
Industry Context
The SPAC market, particularly for companies targeting the healthcare and pharmaceutical sectors, has seen significant activity. However, regulatory scrutiny and market volatility have increased, making target identification and successful de-SPAC transactions more challenging. Companies like DMIIU aim to leverage this environment to bring innovative private companies public.
Regulatory Implications
As a newly formed SPAC, DMIIU faces regulatory oversight from the SEC. The S-1 filing itself is a key regulatory step. Future de-SPAC transactions will be subject to proxy rules, tender offer regulations, and potentially antitrust reviews, depending on the target's industry and size.
What Investors Should Do
- Review the target company's business plan and financials thoroughly once identified.
- Understand the potential for dilution from founder shares, sponsor shares, and warrants.
- Monitor the timeline for the business combination, as failure to complete one within the specified period leads to liquidation.
Key Dates
- 2025-07-21: S-1 Filing Date — This is the initial public filing of the company's registration statement, providing details about its structure, objectives, and risks.
- 2025-07-18: Registration Statement Filed (as of date) — Indicates the date the registration statement was officially submitted to the SEC for review.
Glossary
- SPAC
- A Special Purpose Acquisition Company is a shell company that is formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. (Drugs Made In America Acquisition II Corp. is a SPAC, and its entire business model revolves around finding and merging with a target company.)
- S-1 Filing
- The initial registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document provides the foundational information about DMIIU's formation, objectives, and risks to potential investors.)
- De-SPAC Transaction
- The business combination transaction where a SPAC merges with or acquires a target company, thereby taking the target company public. (This is the critical event for DMIIU; its success hinges on completing a de-SPAC transaction.)
- Blank Check Company
- A company with no commercial operations, formed to raise capital to finance a specific business or to make an acquisition. (This classification highlights DMIIU's nature as a SPAC with no existing business operations.)
- Dilution
- The reduction in the ownership percentage of a shareholder when a company issues new shares. (Investors in DMIIU face the risk of dilution from shares issued during the de-SPAC transaction.)
Year-Over-Year Comparison
As this is the initial S-1 filing for Drugs Made In America Acquisition II Corp., there is no prior filing to compare key metrics against. The company is a newly formed entity with no operational history, revenue, or net income. All financial data and risk factors are presented for the first time in this registration statement.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on July 21, 2025 by Lynn Stockwell regarding Drugs Made In America Acquisition II Corp. (DMIIU).